AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as climbing oil, yields amplify inflation fears
- Oil jumps 5%, then pares gains after Trump says no attack on Iran this month
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- CoreWeave stock drops on dilution fears and debt concerns
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
Pharmacyclics (PCYC) Imbruvica CLL Update a Positive for Suitor Abbvie (ABBV) - BMO Capital
April 20, 2015 3:25 PM EDTBMO Capital analyst Alex Arfaei reiterated his Outperform rating and $68 price target on Abbvie (NYSE: ABBV) as Pharmacyclics' (NASDAQ: PCYC)... More



